The EPS beat is modest and the company remains pre-revenue with no near-term revenue catalyst. The key catalyst to watch is completion of the rolling BLA submission for SPS in Q4 2026 and potential priority review. Given the historical pattern of negative stock reactions to similar filings, traders should be cautious and wait for clearer regulatory milestones before establishing positions.
Price Chart
Executive Summary
Kyverna Therapeutics reported Q2 2026 net loss of $0.63 per share, beating consensus of -$0.68 by 7.4%. The company highlighted progress in its rolling BLA submission for miv-cel in stiff person syndrome, RMAT designation for naSPMS, and reiterated cash runway into 2028. Despite the EPS beat, the stock has historically declined on similar neutral-to-positive reports, and the company remains pre-revenue with no near-term catalyst for commercialization before 2027.
Key Financial Metrics
Key Facts
- Net loss per share of $0.63 beat consensus of -$0.68 (7.4% beat)
- Cash, cash equivalents, and marketable securities of $199.4M as of June 30, 2026
- R&D expenses were $24.8M, G&A expenses were $14.8M for Q2 2026
- Rolling BLA submission for miv-cel in SPS on track for completion in Q4 2026
- RMAT designation granted for miv-cel in non-active secondary progressive multiple sclerosis
- Enrollment in KYSA-6 Phase 3 trial in gMG expected to be completed by mid-2027
- Operating runway reiterated into 2028
Financial Impact
Net loss of $38.3M for Q2 2026, with cash burn of ~$80M in H1 2026; cash runway into 2028
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products
- BLA submission for SPS may face delays or require additional data
- Cash burn rate of ~$80M per half-year may require future capital raises
- Historical stock performance shows negative reactions to similar filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343142 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G | $5.83 $6.04 | ▲ +3.60% | ▲ +3.27% | $5.27 (−9.61%) |
Sep 24, 2026 4w ago | 8-K | $6.99 $6.81 | ▼ −2.58% | ▼ −3.12% | $5.27 (−24.61%) |
Aug 11, 2026 10w ago | 8-K | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Aug 11, 2026 10w ago | Press Release | $8.05 $8.08 | ▲ +0.37% | ▼ −0.33% | $5.27 (−34.53%) |
Jul 27, 2026 13w ago | 8-K | $7.92 $7.49 | ▼ −5.43% | ▼ −5.67% | $5.27 (−33.46%) |
Jul 9, 2026 15w ago | 8-K | $9.81 $8.49 | ▼ −13.51% | ▼ −13.94% | $5.27 (−46.28%) |
Jun 11, 2026 19w ago | Institutional Cluster | $8.06 $8.15 | ▼ −1.18% | ▲ +0.58% | $5.27 (+34.57%) |
May 4, 2026 25w ago | 8-K | $9.00 $9.21 | ▲ +2.33% | ▲ +1.54% | $5.27 (−41.44%) |
Apr 22, 2026 26w ago | 8-K | $10.23 $8.95 | ▼ −12.51% | ▼ −12.12% | $5.27 (−48.48%) |
Apr 20, 2026 27w ago | Press Release | $11.25 $9.71 | ▼ −13.69% | ▼ −13.04% | $5.27 (−53.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers